ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑driven, scalable manufacturing platform for viral and non‑viral gene therapies. The program will integrate machine learning, computational modeling, and real‑world manufacturing data to accelerate process development, reduce optimization cycles, and improve production robustness across gene‑therapy modalities. BioCurie will coordinate a consortium including Caring Cross, St. Jude Children’s Research Hospital, and Center for Breakthrough Medicines, with the goal of replacing trial‑and‑error process development with predictive simulations and closed‑loop engineering. The award is intended to de‑risk manufacturing and lower time and cost barriers to broader clinical and commercial access. Source: ARPA‑H announcement and BioCurie statement.